Sun Pharma Chief: We Are Not 'All In' In Biologics
CEO Remains 'Very Tentative,' Investment Still 'Very Large'
Sun stays “tentative” about a large exposure in the biosimilars segment while also outlining its approach to commercialize some diverse pipeline assets including an early stage GLP-1 receptor agonist.
